Katharine Batt, MD, MSc

home / authors / katharine-batt-md-msc

Articles

August 13th 2019

The Potential Impact of CAR T-Cell Treatment Delays on Society

Julia Thornton Snider, PhD Michelle Brauer, BS Rebecca Kee, BA Katharine Batt, MD, MSc Pinar Karaca-Mandic, PhD Jie Zhang, PhD Dana P. Goldman, PhD

Treatment delays limit the social value generated by chimeric antigen receptor (CAR) T-cell therapy for the treatment of pediatric acute lymphoblastic leukemia and diffuse large B-cell lymphoma.

April 17th 2018

The Well-Being of Long-Term Cancer Survivors

Jeffrey Sullivan, MS Julia Thornton Snider, PhD Emma van Eijndhoven, MS, MA Tony Okoro, PharmD, MPH Katharine Batt, MD, MSc Thomas DeLeire, PhD

This study compares the well-being of long-term cancer survivors with that of US residents of similar age and demographic characteristics, patients recently diagnosed with cancer, and individuals with chronic illness.

October 25th 2017

The Option Value of Innovative Treatments for Non–Small Cell Lung Cancer and Renal Cell Carcinoma

Julia Thornton Snider, PhD Katharine Batt, MD, MSc Yanyu Wu, PhD Mahlet Gizaw Tebeka, MS Seth Seabury, PhD

Option value is the benefit a therapy provides patients by enabling them to survive to the next innovation.